“Primary Hyperoxaluria Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Hyperoxaluria Market.

The Primary Hyperoxaluria Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Primary Hyperoxaluria Pipeline Report:

• Companies across the globe are diligently working toward developing novel Primary Hyperoxaluria treatment therapies with a considerable amount of success over the years. 
• Primary Hyperoxaluria companies working in the treatment market are Chinook Therapeutics, Cantero Therapeutics, BioMarin Pharmaceutical, Inc, OxThera, Dicerna Pharmaceuticals, Inc., and others, are developing therapies for the Primary Hyperoxaluria treatment 

• Emerging Primary Hyperoxaluria therapies in the different phases of clinical trials are- CHK-336, BBP-711, BMN 25, Oxabact, Nedosiran, and others are expected to have a significant impact on the Primary Hyperoxaluria market in the coming years.   
• In June 2023, Results from a Phase I trial examining CHK-336, an oral small molecule LDHA inhibitor under development for primary hyperoxaluria (PH) and other kidney stone problems, were released by Chinook Therapeutics
• In February 2022, In order to assess the safety, pharmacokinetics, and efficacy of Nedosiran in paediatric patients from birth to 11 years old with primary hyperoxaluria and reasonably intact renal function, Dicerna Pharmaceuticals, Inc. started a Phase II open-label multicenter trial.
• In December 2021, The completion of the acquisition of Dicerna Pharmaceuticals, Inc. was announced by Novo Nordisk. Novo Nordisk has bought all outstanding shares of common stock of Dicerna for a price of USD 38.25 per share in cash, without interest, and less any relevant tax withholding, following the expiration of Novo Nordisk’s cash tender offer for Dicerna. 

Primary Hyperoxaluria Overview

A series of rare inherited metabolic illnesses known as Primary Hyperoxaluria (PH) are characterized by the buildup of the chemical oxalate in the kidneys and other organ systems of the body. A particular enzyme that typically inhibits the accumulation of oxalate is absent from affected people.

Get a Free Sample PDF Report to know more about Primary Hyperoxaluria Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/primary-hyperoxaluria-pipeline-insight

Emerging Primary Hyperoxaluria Drugs Under Different Phases of Clinical Development Include:

• CHK-336: Chinook Therapeutics
• BBP-711: Cantero Therapeutics
• BMN 255: BioMarin Pharmaceutical, Inc
• Oxabact: OxThera
• Nedosiran: Dicerna Pharmaceuticals, Inc.

Primary Hyperoxaluria Route of Administration

Primary Hyperoxaluria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Primary Hyperoxaluria Molecule Type

Primary Hyperoxaluria Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Primary Hyperoxaluria Pipeline Therapeutics Assessment

• Primary Hyperoxaluria Assessment by Product Type
• Primary Hyperoxaluria By Stage and Product Type
• Primary Hyperoxaluria Assessment by Route of Administration
• Primary Hyperoxaluria By Stage and Route of Administration
• Primary Hyperoxaluria Assessment by Molecule Type
• Primary Hyperoxaluria by Stage and Molecule Type

DelveInsight’s Primary Hyperoxaluria Report covers around 8+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Primary Hyperoxaluria product details are provided in the report. Download the Primary Hyperoxaluria pipeline report to learn more about the emerging Primary Hyperoxaluria therapies

Some of the key companies in the Primary Hyperoxaluria Therapeutics Market include:

Key companies developing therapies for Primary Hyperoxaluria are – Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, Allena Pharmaceuticals, and others.

Primary Hyperoxaluria Pipeline Analysis:

The Primary Hyperoxaluria pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Primary Hyperoxaluria with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Hyperoxaluria Treatment.
• Primary Hyperoxaluria key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Primary Hyperoxaluria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Primary Hyperoxaluria market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Primary Hyperoxaluria drugs and therapies

Primary Hyperoxaluria Pipeline Market Drivers

• Rising Prevalence of Primary hyperoxaluria, increasing demand for disease specific novel treatments are some of the important factors that are fueling the Primary Hyperoxaluria Market.

Primary Hyperoxaluria Pipeline Market Barriers

• However, high cost of treatment and diagnosis for Hyperoxaluria, limited research and development for treatment and other factors are creating obstacles in the Primary Hyperoxaluria Market growth.

Scope of Primary Hyperoxaluria Pipeline Drug Insight    

• Coverage: Global
• Key Primary Hyperoxaluria Companies: Chinook Therapeutics, Cantero Therapeutics, BioMarin Pharmaceutical, Inc, OxThera, Dicerna Pharmaceuticals, Inc., and others
• Key Primary Hyperoxaluria Therapies: CHK-336, BBP-711, BMN 25, Oxabact, Nedosiran, and others
• Primary Hyperoxaluria Therapeutic Assessment: Primary Hyperoxaluria current marketed and Primary Hyperoxaluria emerging therapies
• Primary Hyperoxaluria Market Dynamics: Primary Hyperoxaluria market drivers and Primary Hyperoxaluria market barriers 

Request for Sample PDF Report for Primary Hyperoxaluria Pipeline Assessment and clinical trials

Table of Contents 

1. Primary Hyperoxaluria Report Introduction

2. Primary Hyperoxaluria Executive Summary

3. Primary Hyperoxaluria Overview

4. Primary Hyperoxaluria- Analytical Perspective In-depth Commercial Assessment

5. Primary Hyperoxaluria Pipeline Therapeutics

6. Primary Hyperoxaluria Late Stage Products (Phase II/III)

7. Primary Hyperoxaluria Mid Stage Products (Phase II)

8. Primary Hyperoxaluria Early Stage Products (Phase I)

9. Primary Hyperoxaluria Preclinical Stage Products

10. Primary Hyperoxaluria Therapeutics Assessment

11. Primary Hyperoxaluria Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Primary Hyperoxaluria Key Companies

14. Primary Hyperoxaluria Key Products

15. Primary Hyperoxaluria Unmet Needs

16 . Primary Hyperoxaluria Market Drivers and Barriers

17. Primary Hyperoxaluria Future Perspectives and Conclusion

18. Primary Hyperoxaluria Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services